A 12-month clinical study of LA-2585 (45.0 MG): A new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer

Journal of Urology

Volumn 175, Issue 2, 2006, Pages 533-536

  Crawford, E David ^a,g   Sartor, Oliver ^c   Chu, Franklin ^d   Perez, Ramon ^e   Karlin, Gary ^f   Garrett, J Steve ^b  

^a University of Colorado   (United States)

^b QLT Inc   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d San Bernardino Urological Associates   (United States)

^e Urology Health Center   (United States)

^f Lawrenceville School   (United States)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

Cinical trials; Luprolide; Postate; Postate cancer; Postate specific antigen

Indexed keywords

LA 2585; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG DELIVERY SYSTEMS; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SUBCUTANEOUS TISSUE; TIME FACTORS;

EID: 30344486309     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00161-8     Document Type: Article

References (11)

1. R. Sharifi, R.C. Bruskewitz, M.C. Gittleman, S.D. Graham Jr., P.B. Hudson, B. Stein Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer Clin Ther 18 1996 647
2. R. Millikan, C. Logothetis Update of the NCCN guidelines for treatment of prostate cancer Oncology (Williston Park) 11 1997 180
3. R.R. Bahnson, G.E. Hanks, R.P. Huben, P. Kantoff, J.M. Kozlowski, M. Kuettel NCCN Practice Guidelines for Prostate Cancer Oncology (Williston Park) 14 2000 111
4. U.W. Tunn, U. Bargelloni, S. Cosciani, G. Fiaccavento, S. Guazzieri, F. Pagano Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer Urol Int 60 suppl 1998 9
5. R. Sharifi, L.D. Knoll, J. Smith, E. Kramolowsky Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer Urology 51 1998 271
6. J.E. Fowler Jr., J.E. Gottesman, C.F. Reid, G.L. Andriole Jr., M.S. Soloway Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer J Urol 164 2000 730
7. R. Perez-Marreno, F.M. Chu, D. Gleason, E. Loizides, B. Wachs, R.C. Tyler A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer Clin Ther 24 2002 1902
8. M.G. Oefelein, R. Cornum Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapythe case for monitoring serum testosterone and a treatment decision algorithm J Urol 164 2000 726
9. H.B. Ravivarapu, K.L. Moyer, R.L. Dunn Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide Int J Pharmacol 194 2000 181
10. J.S. Davidson, I.K. Wakefield, R.P. Millar Absence of rapid desensitization of the mouse gonadotropin-releasing hormone receptor Biochem J 300 1994 299
11. E.M. Messing, J. Manola, M. Sarosdy, G. Wilding, E.D. Crawford, D. Trump Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer New Engl J Med 341 1999 1781